Chemomab Therapeutics (CMMB) to Release Quarterly Earnings on Monday

Chemomab Therapeutics (NASDAQ:CMMB) is anticipated to post its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 6, 2026 at 7:00 AM ET.

Chemomab Therapeutics Stock Down 4.3%

Shares of Chemomab Therapeutics stock opened at $1.57 on Monday. The business has a fifty day simple moving average of $1.71 and a 200-day simple moving average of $2.53. Chemomab Therapeutics has a fifty-two week low of $1.40 and a fifty-two week high of $7.08. The firm has a market cap of $9.67 million, a price-to-earnings ratio of -0.53 and a beta of 0.56.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CMMB. Weiss Ratings reissued a “sell (d-)” rating on shares of Chemomab Therapeutics in a report on Monday, December 29th. Zacks Research lowered shares of Chemomab Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 18th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Chemomab Therapeutics has a consensus rating of “Hold” and a consensus target price of $25.00.

Institutional Trading of Chemomab Therapeutics

A hedge fund recently bought a new stake in Chemomab Therapeutics stock. ADAR1 Capital Management LLC bought a new position in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 80,000 shares of the company’s stock, valued at approximately $132,000. ADAR1 Capital Management LLC owned 1.30% of Chemomab Therapeutics as of its most recent SEC filing. 46.05% of the stock is owned by institutional investors.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.